Heather Raymon Biography and Net Worth

Heather Raymon, Ph.D., has 25 years of biotech and biopharma industry experience. Prior to Artiva, Dr. Raymon was Executive Director, Early Development Program Leadership at Celgene/Bristol Myers Squibb, where she was leading multiple clinical-stage programs in immuno-oncology and neuroscience. Prior to that, Dr. Raymon was Sr. Director and Head of Pharmacology at Celgene, where she built a department that was responsible for developing pharmacology data packages in support of regulatory filings in oncology and inflammation/immunology. Dr. Raymon started her biotech career at Signal Pharmaceuticals working in neurobiology and cellular and molecular pharmacology before the company was acquired by Celgene. Dr. Raymon received her B.S. in biology from SUNY Albany, a Ph.D. in pharmacology and toxicology at UC Irvine, and was a postdoctoral fellow at Salk Institute for Biological Studies and UC San Diego.

What is Heather Raymon's net worth?: The estimated net worth of Heather Raymon is at least $1.46 million as of May 19th, 2026. Raymon owns 148,228 shares of Artiva Biotherapeutics stock worth more than $1,455,599 as of June 23rd. This net worth estimate does not reflect any other investments that Raymon may own. Learn More about Heather Raymon's net worth.
How do I contact Heather Raymon?: The corporate mailing address for Raymon and other Artiva Biotherapeutics executives is , , . Artiva Biotherapeutics can also be reached via phone at (858) 267-4467 and via email at [email protected]. Learn More on Heather Raymon's contact information.
Has Heather Raymon been buying or selling shares of Artiva Biotherapeutics?: Within the last three months, Heather Raymon has sold $27,885.95 in Artiva Biotherapeutics stock. Most recently, Heather Raymon sold 3,095 shares of the business's stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a transaction totalling $27,885.95. Following the completion of the sale, the senior vice president now directly owns 148,228 shares of the company's stock, valued at $1,335,534.28. Learn More on Heather Raymon's trading history.
Who are Artiva Biotherapeutics' active insiders?: Artiva Biotherapeutics' insider roster includes Fred Aslan (President and Chief Executive Officer), Subhashis Banerjee (Insider), Jennifer Bush (COO), Christopher Horan (Insider), and Heather Raymon (SVP). Learn More on Artiva Biotherapeutics' active insiders.
Are insiders buying or selling shares of Artiva Biotherapeutics?: In the last year, Artiva Biotherapeutics insiders bought shares 9 times. They purchased a total of 9,501,755 shares worth more than $103,750,036.39. In the last year, insiders at the sold shares 9 times. They sold a total of 113,602 shares worth more than $741,174.90. The most recent insider tranaction occured on June, 16th when Director Ra Capital Management, L.P. bought 124,893 shares worth more than $1,110,298.77. Insiders at Artiva Biotherapeutics own 21.4% of the company. Learn More about insider trades at Artiva Biotherapeutics.
Information on this page was last updated on 6/16/2026.

Heather Raymon Insider Trading History at Artiva Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/19/2026	Sell	3,095	$9.01	$27,885.95	148,228

Heather Raymon Buying and Selling Activity at Artiva Biotherapeutics

Artiva Biotherapeutics Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Today's Range

Now: $9.73

$9.21

$10.00

50 Day Range

MA: $9.26

$6.80

$13.39

2 Week Range

Now: $9.73

$1.47

$14.53

Volume

215,878 shs

Average Volume

372,408 shs

Market Capitalization

$240.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.4